Category Archives: Immunology

Anaesthetic allergy

Reactions to local anaesthetics are often reported, but given how often they are used, most turn out not to be allergic but rather toxic (eg to parabens or sulphite preservative) or autonomic. Where allergy is confirmed, it is often of a delayed hypersensitivity type eg 24-72 hours after exposure. Beware latex allergy and C1 esterase inhibitor deficiency too. Local anaesthetics come in 2 main groups, the esters (procaine, benzocaine) and the amides (lidocaine, bupivocaine). Cross-reactivity is common among the esters but not among the amides or between the 2 groups. Neomycin sensitivity may contribute to a reaction.

Exercise induced anaphylaxis

Rare but well recognized allergic condition, about half related to a food trigger.

Anaphylaxis can occur with any degree of exercise, does not need to be extreme, but typically follows submaximal exercise pretty quickly.  Deaths are fortunately rare.

Possible mechanisms:

  • Exercise induced increase in gastric permeability
  • increased tissue transglutaminase activity in gut
  • Exercise induced blood flow redistribution
  • Mast cell heterogeneity
  • Basophil trigger by increased plasma osmolality
  • Mast cell trigger by acidosis

All sound plausible but little evidence!

Co-factors play a role in many cases eg alcohol (but unpredictable), NSAIDs (85% will have reduced threshold, and severity increases too), infection, heat/cold – some evidence too for menstruation, anti-acids, stress, sleep deprivation (as in anaphylaxis).  Co-factors also multiply risk of reaction.

Food triggers

Mostly wheat, including hidden sources eg soap, shampoo, cream.

Diagnosis

SPT useful, also IgE omega-5-gliadin.  But gold standard is provocation test (and still only 70% sensitive).  No uniform protocol – use same as for exercise induced bronchoconstriction? Do 1 hour after meal with suspected trigger.

Management

Prescribe adrenaline auto-injector.  Avoid exercise 4-6 hours after food intake.  Discuss unplanned exercise!

HIV/AIDS

2015 37m worldwide living with HIV, vast majority in Sub-Saharan Africa. Growth is N Africa and Middle East.

20 years since introduction of ART. Still over 1 m deaths per year. Only about a third have access to ART. $250 per child per year.

West Africa seroprevalence only 1-2%, S Africa 25% of sexually active!!!

Treatment for pregnant women actually very good coverage in South and East Africa, much poorer elsewhere.

WHO now recommends treatment for everyone at diagnosis, regardless of CD4, symptoms etc!

In UK 5000 new cases per year, peaked in 2005 (8000), pretty stable now, still mostly migrant associated. Average age of HIV pos child is now 13.6!!! No neonatal cases in Scotland for years.

Majority of known patients have undetectable viral load!

Maternal transmission

Previous advice to breast feed exclusively for 6/12 then stop, now WHO say at least 10-12 months, with no recommendation on stopping. Mixed feeding is now considered acceptable. But this weighs benefits of breast feeding against low rate of transmission of under 2%.

In UK, completely discourage breast feeding, but “not a child protection issue”! Still controversial. Check with your local team!

Transition

Focus now on optimisation of health status through childhood rather than survival! Worry that significant numbers of deaths in survivors of childhood HIV.

Future

Treatment interruptions (not good outcomes in adults)?  Reduction in lab monitoring? Still new (delayed) toxicities eg portal hypertension with DDI. Depot injections!

Treatment

Kaletra + nevirapine first line. Commissioning in England influences treatment recommendations. PENTA 2016 now recommends ART for all children.

Dolutegravir has best results, side effect profile and low interactions (Integrase strand transfer inhibitors (INSTIs)).

Hydrolysed Formulas

Alternatives and variations on cow’s milk based formulas:

  • Extensively hydrolysed – protein is broken down so good for cow’s milk protein allergy.  Not very nice tasting!  Can be whey-based eg Pepti (which includes lactose, so more palatable but no good for lactose intolerance), else casein-based eg Nutramigen (lactose free).
  • Partially hydrolysed – better tasting but symptoms may persist if true allergy
  • Anti-reflux “stay down”
  • Soya – good for cow’s milk protein allergy but cross reactivity can occur, plus theoretical phyto-oestrogen effect so avoid if under 6 months.  But the only one you can use if you are vegan or have galactosaemia.

Aptamil Pepti is made by Milupa (which is where GP’s will find it on electronic prescribing system). Not suitable for vegetarians and not Halal!

Some are lactose free, others not. Some have medium chain triglycerides as main fat source, eg Pepti Junior, Pregestimil, Peptisorb.

Nutramigen contains prebiotics – should therefore not be given to preterm babies (theoretical risk of gut translocation), and should be made up at room temperature (so not suitable for prep machines).

For those who require a vegetarian or halal diet, the only suitable extensively hydrolysed infant milk is SMA Althéra. Of the amino acid formulas, all are halal, and Neocate/Alfamino are vegetarian. None are vegan friendly.

SMA Alfamino does not have coconut oil, unlike some of the others.  No evidence that there is sufficient coconut protein in formula to cause an allergic reaction but it often gets accused of suspected reactions.

Complement deficiency

Complement cascade can be triggered by classical (antibody binding to antigen, but also directly by C-reactive protein an other substances), lectin (mannan binding lectin, which recognise glycoproteins not typically found in higher order animals) or alternative pathways.  The alternative pathway is the oldest, and constitutes a constant low level autoactivation, at the ready to explode!  Properdin acts here, and may ineract directly with bacteria.

Deficiency can cause susceptibility to infection, but see also hereditary angioedema and atypical HUS.

C3 is the common factor, so deficiency leads to severe infection with encapsulated organisms eg Pneumococcus, Haemophilus, Meningococcus.  Deficiency in terminal and alternative pathways lead almost exclusively to problems with meningococcus!

Properdin

Stabilizes C3/C5 convertase enzymes.  Deficiency (X-linked) associated with fulminant meningococcal infection, especially with unusual types eg W135, Y!  Phagocytosis more important for type B disease? Life time risk for affected individual is about 50%!  Interestingly, mean age of presentation is 14yrs.  Recurrence is actually unusual, presumably due to intact immune memory.

Subtypes characterized by absent, low level and dysfunctional properdin seen.  Standard screening with C3, C4 and CH50 are normal.  Good family history is more important.

Good antibody responses to Men ACWY vaccine.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905414/

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952982/

 

https://www.ncbi.nlm.nih.gov/pubmed/19758139

The GINI study

German study from 1998.

Some potential benefit from using hydrolyzed formula in terms of preventing allergy.  The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was:

  • 0.87 (95% CI, 0.77-0.99) for partially hydrolysed whey-based formula (pHF-W),
  • 0.94 (95% CI, 0.83-1.07) for extensively hydrolysed whey-based formula (eHF-W) eg Pepti, and
  • 0.83 (95% CI, 0.72-0.95) for extensively hydrolysed casein-based formula (eHF-C) eg Nutramigen compared with standard cow’s milk formula.

The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively.

In the per-protocol analysis (ie where patients stuck to protocol) effects were stronger (0.49 for eczema at 1yr). The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis.

[J Allergy Clin Immunol. 2013 Jun;131(6):1565-73. doi: 10.1016/j.jaci.2013.01.006. ]

Cochrane review 2009 biased towards GINI data.  Since then big Melbourne study (MACS) not in favour; per protocol analysis for eczema at age 1 yr did not show any benefit (0.55-1.93).

Even with GINI, NNT could be as high as 80!

[http://onlinelibrary.wiley.com/doi/10.1111/pai.12138/full]

15 yr follow up of GINI study – between 11 and 15 years,

  • prevalence of asthma was reduced in the eHF‐C group compared to CMF (OR 0.49, 95% CI 0.26–0.89)
  • cumulative incidence of atopic rhinitis was lower in eHF‐C (risk ratio (RR) 0.77, 95% CI 0.59–0.99]) and the AR prevalence lower in pHF‐W (OR 0.67, 95% CI 0.47–0.95) and eHF‐C (OR 0.59, 95% CI 0.41–0.84).
  • cumulative incidence of eczema was reduced in pHF‐W (RR 0.75, 95% CI 0.59–0.96) and eHF‐C (RR 0.60, 95% CI 0.46–0.77), as was the eczema prevalence between 11 and 15 years in eHF‐C (OR 0.42, 95% CI0.23–0.79).
  • No significant effects were found in the eHF‐W group on any manifestation,nor was there an effect on sensitization with any formula.

[Allergy 2016; 71: 210–219. http://onlinelibrary.wiley.com/doi/10.1111/all.12790/abstract]

The EAT study

2016 study of early introduction of six common food allergens into the diet of 1303 breastfed 3 month old infants recruited from a general (not high risk) population.

Randomized.  Breast feeding needed to be maintained until at least 5 months, at least 5 weeks of at least 75% of recommended dose (ie 3g of protein per week) between 3 and 6 months.

2g protein twice weekly was recommended – 2g is roughly:

  • 2 teaspoons peanut butter or 21 Bamba pieces
  • 1 small pot yogurt
  • 1/2 small egg
  • 10g fish
  • 1tsp tahini

In an intention to treat analysis, 7.1% of the standard introduction group (at parental discretion) and 5.6% of the early introduction group developed food allergy to one or more of the six intervention foods (peanuts, egg, cow’s milk, sesame, white fish and wheat) up to 3 years of age (p=0.32, ie no difference).

However, when the analysis was adjusted for adherence to early introduction, there was a statistically significant 67% lower rate of food allergy in the early introduction group (2.4% vs 6.4%; p=0.03), with no cases of peanut allergy (rate was 2.5% in control group) and 75% less egg allergy (1.4% vs 5.5%).  Rate of skin prick test positivity significantly lower for peanut, egg, milk, sesame.

Cooked egg works! Increasing dose, increasing effect.  Modelling suggests 2g protein weekly effective.

Safe!

However, poor adherence to the study protocol (only 32% managed to follow early introduction fully) highlights the challenges around introducing solids.

[Michael Perkins, DOI: 10.1056/NEJMoa1514210]

Chronic Granulomatous Disease

A neutrophil defect, prediposes to certain characteristic organisms. Frustrated neutrophils cause granulomas, hence the name: these are responsible for some other characteristic features of the disease.

Due to NADPH oxidase mutations, causing reduced oxidative burst (needed by neutrophils to kill pathogens after phagocytosis). Various types depending on which subunit affected. X linked gp91phox def (ie NADPH OXidase, due to CYBB gene defect) is severe, p47phox is autosomal and milder (NCF1 gene, partial activity retained). Other gene defects are CYBA and NCF2, funnily enough, and RAC2. Phenotype varies even between mono twins (factors?). Since non-oxidative killing is then the only remaining immune mechanism, the most important pathogens are catalase positive (an enzyme to make bugs resistant to the peroxide and superoxide produced by neutrophils or by the bacteria themselves as a toxic byproduct). Register exists in UK.

Usually present by 2 yrs but occ not until adulthood. Most commonly lymphadenitis (often culture negative), skin infections (esp perianal), pneumonia. Hepatomegaly is a clue. Other sites of infection are osteomyelitis, liver abscesses (distinctive, fibrous capsule, septated, thick contents – vague presentation, blood cultures usually negative so low index of suspicion).

Probably not the superoxides themselves that are important; MPO deficiency does not tend to present with infections! Critical step is probably degranulation of primary granules, with release of elastases etc. Superoxides probably deal with toxic metabolites rather than doing the killing.

Chronic inflammatory problems occur (due to having intact upregulated phagocytic activity with reduced apoptosis):

  • BCG causes lymphadenitis in CGD, but does not disseminate.
  • colitis (characterized by pigment laden macrophages, quite specific for CGD but not very sensitive). Seen in 45% of X-linked, 10% of autosomal recessive. Tends to present with abdo pain rather than frank bleeding, often subclinical, may account for FTT.
  • lupus like rash and illness
  • Poor wound healing (classically dehiscence at 10/7 post op, non-purulent)
  • cystitis
  • pericarditis
  • chorioretinitis
  • Hollow organs may become obstructed by granulomas esp oesophagus, gastric outlet, bladder.
  • pulmonary fibrosis

Mums who are carriers of CGD can be symptomatic even with fairly decent percentages of functional neutrophils incl aspergillus! Due to lyonization.  Onset variable.

Diagnosis

Nitroblue tetrazolium (NBT) test now replaced by Dihydrorhodamine test on flow cytometer (false positive esp in preterm so always check with reference lab). Only takes 15 mins!

The organisms found are also characteristic:

  • Staphylococcus aureus – found in most liver abscesses as well as in skin
  • Enterobacteria – Enterobacter, E coli, Salmonella, Klebsiella, Aerobacter, Serratia, Yersinia, Proteus
  • Aspergillus – mostly fumigatus but A. nidulans is emerging in US, and Candida albicans, Scedosporium apiospernum and Chyrosporium zonatum reported. Can be acute, esp after inhalation eg digging in garden. Biopsy may be needed to make diagnosis. Steroids useful for severe inflammatory disease!!!
  • Burkholderia cepacia – looks identical to Pseudomonas, so any Ps not specified as aeruginosa should be considered suspect! (Pseudomonas itself is catalase positive but susceptible to non-oxidative killing so is not a problem).
  • Septicaemia is v rare ! – but may be seen with B. cepacia.
  • Nocardia common in US, rare in Europe – gram positive soil organism, forms filaments like a fungus. Usually pneumonia but also skin, CNS. Sensitive to co-trimoxazole.
  • Actinomycosis – even though catalase negative!

Note that you do NOT see PCP, strep, onychomycosis (despite susceptibility to fungus) or lymphomas (cf granulomas).

Patients are often anaemic with an iron-deficient pattern but resistant to iron supplementation (except in bowel disease, ?vitamin B12 def). ESR is often raised even when well. Less of a problem with CRP.

Management

Co-trimoxazole prophylaxis (daily dosing, not 3x weekly as in PCP prophylaxis) good because active against typical bugs, and intracellular. Itraconazole is prophylactic vs Aspergillus.

Avoid BCG because of tendency to form abscess.

Cipro and Fluclox good for first line – effective against typical organisms, and cipro acts intracellularly. In serious pneumonia, empirical treatment should consist of Ceftazidime/Meropenem, Fluclox and Amphotericin. Because of the range of possible organisms, bacteriological diagnosis should not be delayed and tissue biopsy sought if non-invasive methods unsuccessful.

Steroids for colitis, cystitis and obstructive granulomatous disease. Also for poor wound healing!

Other adjuncts:

  • Voriconazole is an effective oral antifungal, so useful when no tissue diagnosis (beware accumulation of amphotericin with long term use, causing permanent renal damage).
  • Interferon (IFN) gamma – effective as prophylaxis in large Multicentre study, but strong centre effect with less benefit in Europe (in fact the lowest incidence seen with antibiotic prophylaxis) so not universally used (but safe). Less evidence in established infection but that’s when it tends to get used! Increases NO production by neutrophils, by improved RNA splicing efficiency(?). Give three times a week by subcut injection; side effect is fever and flu-like symptoms. Better antifungals mean it is used less now.
  • Granulocyte infusions (apheresed from donors after GCSF priming) can be done every 1-2 days (or instilled directly into lesions) but rarely needed now with better antifungals. Increases risk of reaction to Ambisome, plus you become sensitized, which will hinder transplant prospects. Can support infected kids through BMT.
  • Surgery may be necessary to remove infected tissue, may help get positive culture.
  • BMT is indicated at diagnosis if a matched donor is available.
  • Gene therapy has produced transient improvements only.

Median survival 30 years – NB compliance with prophylaxis by adolescents. So consider transplant.

[Clin Exp Imm 122(1); October 2000 pp 1-9 GOLDBLATT, D; THRASHER, AJ]

Recurrent boils

Potentially symptom of diabetes, chronic granulomatous disease, Hyper IgE syndrome – but more usually just an individual thing, or a nasty strain of staphlycoccus aureus.

GOS says if otherwise well (no other abscesses, no colitis, no weird organisms eg Serratia) then consider eradication with:

  • Naseptin – a medication taken four times a day for a period of 10 day.s
  • Chlorhexidine shower or bath and hairwash every day for a period of 14 days.
  • Keep a separate towel for each member of the family, change for a clean towel every two days and wash the dirty towels on a hot wash cycle.

[http://www.gosh.nhs.uk/medical-information-0/search-medical-conditions/recurrent-boils]

Non-specific effects of childhood vaccines

Systematic review.

BCG and Measles vaccine appear to reduce all cause mortality, not just TB and Measles (relative risk 0.7 in trials, 0.5 in observational studies, roughly same for both vaccines).

That’s wonderful, until you see that DTP vaccine appears to increase mortality (in 7 of 9 observational studies).

So are live vaccines “immune boosting” in some general way, whereas inactivated vaccines are not, or actually deleterious?

Large proportion of data from studies in Guinea-Bissau so high risk of bias!

[BMJ 2016; 355]

Systematic review of immunological effects of BCG found evidence of changes in non-specific immunological variables (eg IFN-gamma prodution, enhanced lymphocyte proliferation in response to candida, HBsAg, staph etc) but inconsistent, dubious clinical relevance, and certainly not geographically generalisable.

Ultimately, better designed studies, linked to epidemiology, needed before policy changes can be justified.